23andMe Stock Forecast, Price & News

23andMe (NASDAQ:ME) Frequently Asked Questions

Is 23andMe a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 23andMe in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" 23andMe stock.
View analyst ratings for 23andMe or view top-rated stocks.

When is 23andMe's next earnings date?

23andMe is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for 23andMe.

How were 23andMe's earnings last quarter?

23andMe Holding Co. (NASDAQ:ME) posted its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.09.
View 23andMe's earnings history.

What guidance has 23andMe issued on next quarter's earnings?

23andMe issued an update on its FY 2022 earnings guidance on Thursday, December, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $250 million-$260 million, compared to the consensus revenue estimate of $256.12 million.

What price target have analysts set for ME?

2 analysts have issued twelve-month price targets for 23andMe's shares. Their forecasts range from 13.00 to 14.00. On average, they anticipate 23andMe's stock price to reach 13.50 in the next twelve months. This suggests a possible upside of 76.5% from the stock's current price.
View analysts' price targets for 23andMe or view top-rated stocks among Wall Street analysts.

Who are 23andMe's key executives?

23andMe's management team includes the following people:

• Ms. Anne Wojcicki, Co-Founder, CEO, Pres & Director
• Mr. Steven J. Schoch, CFO & Treasurer (Age 62, Pay $582.83k)
• Ms. Kathy L. Hibbs J.D., Esq., Chief Legal & Regulatory Officer and Sec. (Age 57, Pay $558.53k)
• Dr. Kenneth J. Hillan, Head of Therapeutics (Age 60, Pay $557.62k)
• Ms. Katie Watson, VP of Communications
• Mr. Fred Kohler, VP of People
• Mr. Mike Polcari, VP & Chief Architect
• Mr. David Baker, Chief Security Officer
• Mr. Kumar Iyer, Head of Product
• Dr. Jennifer Low, Head of Therapeutics Devel. (Age 52)

Who are some of 23andMe's key competitors?

Some companies that are related to 23andMe include Maravai LifeSciences (MRVI), Ono Pharmaceutical (OPHLF), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), United Therapeutics (UTHR), CureVac (CVAC), Ascendis Pharma A/S (ASND), Evotec (EVTCY), Jazz Pharmaceuticals (JAZZ), Grifols (GRFS), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), Sarepta Therapeutics (SRPT) and Biohaven Pharmaceutical (BHVN).
View all of ME's competitors.

What is 23andMe's stock symbol?

23andMe trades on the NASDAQ under the ticker symbol "ME."

Who are 23andMe's major shareholders?

23andMe's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Casdin Capital LLC (0.45%), BlackRock Inc. (0.28%), Morgan Stanley (0.28%), Liberty Street Advisors Inc. (0.21%), Geode Capital Management LLC (0.19%) and Millennium Management LLC (0.10%).

Which major investors are selling 23andMe stock?

ME stock was sold by a variety of institutional investors in the last quarter, including Casdin Capital LLC, Millennium Management LLC, Citadel Advisors LLC, Morgan Stanley, Jane Street Group LLC, Wolverine Trading LLC, Advisor Group Holdings Inc., and Raymond James Financial Services Advisors Inc..

Which major investors are buying 23andMe stock?

ME stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Granahan Investment Management Inc. MA, Cambridge Investment Research Advisors Inc., Ionic Capital Management LLC, SG Americas Securities LLC, M&G Investment Management Ltd., and Cubist Systematic Strategies LLC.

How do I buy shares of 23andMe?

Shares of ME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 23andMe's stock price today?

One share of ME stock can currently be purchased for approximately 7.65.

How much money does 23andMe make?

23andMe has a market capitalization of $3.12 billion.

How many employees does 23andMe have?

23andMe employs 572 workers across the globe.

What is 23andMe's official website?

The official website for 23andMe is vgacquisition.com.

Where are 23andMe's headquarters?

23andMe is headquartered at 65 BLEECKER STREET 6TH FLOOR, NEW YORK NY, 10012.

How can I contact 23andMe?

23andMe's mailing address is 65 BLEECKER STREET 6TH FLOOR, NEW YORK NY, 10012. The company can be reached via phone at 650-938-6300.